Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension) [Yahoo! Finance]
Eton Pharmaceuticals, Inc. (ETON)
Last eton pharmaceuticals, inc. earnings: 3/5 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Strong strategic fit with Eton's existing pediatric endocrinology focus Amglidia has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) Potential New Drug Application (NDA) submission in 2026 DEER PARK, Ill., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired the U.S. rights to Amglidia (glyburide oral suspension, known as glibenclamide in Europe) for the treatment of neonatal diabetes mellitus from AMMTeK. “This exciting transaction adds another attractive, patented product candidate to our growing pediatric endocrinology portfolio. In addition, the product aligns with Eton's expertise and wealth of experience in bringing to market liquid and precision dose formulations for pediatric patients,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “C
Show less
Read more
Impact Snapshot
Event Time:
ETON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETON alerts
High impacting Eton Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ETON
News
- Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection) [Yahoo! Finance]Yahoo! Finance
- Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)GlobeNewswire
- Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical TrialGlobeNewswire
- Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) top owners are retail investors with 58% stake, while 26% is held by institutions [Yahoo! Finance]Yahoo! Finance
ETON
Earnings
- 11/12/24 - Beat
ETON
Sec Filings
- 12/20/24 - Form 8-K
- 12/17/24 - Form 8-K
- 12/12/24 - Form 8-K
- ETON's page on the SEC website